Charles River Laboratories International, Inc. Share Price
Equities
CRL
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
193.61 USD | -2.88% | -2.81% | -18.16% |
Capitalization | 10.19B 9.68B 9B 8.02B 14.35B 864B 15.84B 111B 41.41B 354B 38.28B 37.45B 1,531B | P/E ratio 2024 * |
34.2x | P/E ratio 2025 * | 30x |
---|---|---|---|---|---|
Enterprise value | 12.29B 11.67B 10.86B 9.67B 17.3B 1,041B 19.1B 134B 49.94B 427B 46.17B 45.16B 1,846B | EV / Sales 2024 * |
3.05x | EV / Sales 2025 * | 2.87x |
Free-Float |
97.96% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Charles River Laboratories International, Inc.
1 day | -1.76% | ||
1 week | -0.88% | ||
Current month | -0.88% | ||
1 month | +4.57% | ||
3 months | +3.20% | ||
6 months | -8.71% | ||
Current year | -16.54% |
Director | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 31/12/1991 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 30/04/2022 |
Julie Frearson
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2013 |
Manager | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 31/12/2002 |
James Foster
CHM | Chairman | 73 | 31/12/1999 |
Deborah Kochevar
BRD | Director/Board Member | 67 | 28/10/2008 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 1 M€ | -.--% | - | |
2.07% | 5 M€ | -1.80% | - | |
1.08% | 0 M€ | 0.00% | - | |
0.98% | 0 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-1.76% | -0.88% | -0.52% | -43.85% | 10.19B | ||
-1.80% | -0.19% | +55.60% | -26.45% | 43.21B | ||
-1.31% | +0.29% | -6.01% | -23.44% | 36.88B | ||
-1.09% | +1.80% | +11.32% | -8.79% | 26.71B | ||
-1.88% | +0.78% | -21.37% | -20.32% | 17.71B | ||
-0.12% | +0.96% | +55.66% | +98.21% | 16.71B | ||
+3.40% | -1.79% | -45.98% | -84.06% | 16.02B | ||
-1.38% | +0.90% | +18.11% | -35.04% | 12.06B | ||
-2.42% | +0.17% | +23.26% | +66.46% | 10.74B | ||
-0.73% | +0.46% | +3.05% | -20.72% | 9.73B | ||
Average | -0.91% | -0.07% | +9.31% | -9.80% | 20B | |
Weighted average by Cap. | -1.02% | +0.07% | +13.96% | -13.32% |
2024 * | 2025 * | |
---|---|---|
Net sales | 4.03B 3.83B 3.56B 3.17B 5.67B 342B 6.26B 44.07B 16.38B 140B 15.14B 14.81B 605B | 4.11B 3.91B 3.63B 3.24B 5.79B 349B 6.39B 44.97B 16.71B 143B 15.45B 15.11B 618B |
Net income | 302M 287M 267M 237M 425M 25.57B 469M 3.3B 1.23B 10.49B 1.13B 1.11B 45.32B | 342M 325M 302M 269M 482M 29.01B 532M 3.74B 1.39B 11.9B 1.29B 1.26B 51.41B |
Net Debt | 2.1B 1.99B 1.85B 1.65B 2.96B 178B 3.26B 22.95B 8.53B 72.97B 7.89B 7.71B 315B | 1.63B 1.55B 1.44B 1.28B 2.3B 138B 2.54B 17.84B 6.63B 56.7B 6.13B 5.99B 245B |
Date | Price | Change | Volume |
---|---|---|---|
05/12/24 | 193.73 $ | -2.82% | 182,760 |
04/12/24 | 199.35 $ | +0.03% | 436,620 |
03/12/24 | 199.30 $ | -0.97% | 458,614 |
02/12/24 | 201.25 $ | +1.10% | 630,456 |
29/11/24 | 199.06 $ | -0.27% | 287,759 |
Delayed Quote Nyse, December 05, 2024 at 03:06 pm
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
MarketScreener is also available in this country: United States.
Switch edition